Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.39 |
| ▸ | GABRE | P78334 | 1/20 | 0.39 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.39 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.39 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.39 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13221050 | 1.00 | GABRR1 (0.43) | GABRR1SLC1A2TSHRPMP22GABRP | |
| SCHEMBL2811192 | 1.00 | GABRR1 (0.43) | GABRR1SLC1A2TSHRPMP22GABRP | |
| SCHEMBL22160590 | 1.00 | GABRR1 (0.43) | GABRR1SLC1A2TSHRPMP22GABRP | |
| SCHEMBL6335676 | 1.00 | GABRR1 (0.43) | GABRR1SLC1A2TSHRPMP22GABRP | |
| SCHEMBL21402232 | 0.97 | GABRR1 (0.41) | GABRR1SLC1A2TSHRPMP22GABRP | |
| SCHEMBL17743462 | 0.97 | GABRR1 (0.41) | GABRR1SLC1A2TSHRPMP22GABRP | |
| SCHEMBL29951639 | 0.87 | HPSE (0.37) | GABRR1SLC1A2TSHRMC4RLMNA | |
| SCHEMBL11889143 | 0.85 | SLC1A2 (0.38) | GABRR1SLC1A2TSHRPMP22GABRP | |
| SCHEMBL3196556 | 0.83 | — | — | |
| SCHEMBL10179391 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-11260379-B2 | Catalysts and methods for epoxide-based polymerizations | CORNELL UNIVERSITY (US) | 2022-03-01 | — | — | US | disclosed |
| CN-109641878-B | DIPROVOCIM: effective TLR agonist | 斯克里普斯研究学院 | 2021-09-14 | — | — | CN | disclosed |
| US-11040959-B2 | Diprovocims: a new and potent class of TLR agonists | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200384450-A1 | CATALYSTS AND METHODS FOR EPOXIDE-BASED POLYMERIZATIONS | CORNELL UNIVERSITY | 2020-12-10 | — | — | US | disclosed |
| EP-3445758-B1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | SCRIPPS RESEARCH INST (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20200207742-A1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | THE SCRIPPS RESEARCH INSTITUTE | 2020-07-02 | — | — | US | disclosed |
| US-7550487-B2 | Pyrrolidine-3,4-dicarboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1732918-B1 | NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-11-12 | — | — | EP | disclosed |
| EP-1732918-A1 | NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005092881-A1 | NOVEL PYRROLIDINE-3,4-DICARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-06 | — | — | WO | disclosed |
| US-20050215599-A1 | Pyrrolidine-3,4-dicarboxamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-29 | — | — | US | disclosed |
| US-6858626-B2 | Enzyme inhibitor; antiinflammatory agents; osteoporosis | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030139597-A1 | Novel Cyclic hydroxamic acid as metalloproteinase inhibitors | XUE CHU-BIAO (US) | 2003-07-24 | — | — | US | disclosed |
| US-6429213-B1 | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIS AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215599-A1 | Pyrrolidine-3,4-dicarboxamide derivatives | F9, F2, F12 | GABRR1 2352/4885SLC1A2 2466/4885TSHR 1530/4885 |
| US-20200207742-A1 | DIPROVOCIMS: A NEW AND POTENT CLASS OF TLR AGONISTS | TLR1, TLR4, TLR2 | GABRR1 1922/4885SLC1A2 4428/4885TSHR 929/4885 |
| US-20030139597-A1 | Novel Cyclic hydroxamic acid as metalloproteinase inhibitors | MMP9, MMP2, MMP25 | GABRR1 1693/4885SLC1A2 649/4885TSHR 3243/4885 |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | GABRR1 1460/4885SLC1A2 4771/4885TSHR 2359/4885 |
| US-11040959-B2 | Diprovocims: a new and potent class of TLR agonists | TLR1, TLR4, TLR2 | GABRR1 1987/4885SLC1A2 4450/4885TSHR 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.